Concurrent Investment Advisors LLC increased its position in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 131.9% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 53,517 shares of the company's stock after purchasing an additional 30,438 shares during the period. Concurrent Investment Advisors LLC's holdings in Kenvue were worth $1,238,000 as of its most recent filing with the Securities and Exchange Commission.
Several other institutional investors have also added to or reduced their stakes in KVUE. Leo Wealth LLC lifted its holdings in shares of Kenvue by 0.3% during the third quarter. Leo Wealth LLC now owns 151,611 shares of the company's stock worth $3,507,000 after buying an additional 481 shares in the last quarter. Massmutual Trust Co. FSB ADV raised its stake in Kenvue by 6.2% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 8,400 shares of the company's stock worth $194,000 after purchasing an additional 492 shares in the last quarter. Wolff Wiese Magana LLC raised its stake in Kenvue by 0.7% in the 3rd quarter. Wolff Wiese Magana LLC now owns 76,999 shares of the company's stock worth $1,781,000 after purchasing an additional 501 shares in the last quarter. Marathon Capital Management boosted its holdings in Kenvue by 0.3% in the 2nd quarter. Marathon Capital Management now owns 149,699 shares of the company's stock valued at $2,722,000 after purchasing an additional 514 shares during the period. Finally, Poehling Capital Management INC. grew its position in shares of Kenvue by 0.5% during the 2nd quarter. Poehling Capital Management INC. now owns 104,934 shares of the company's stock worth $1,908,000 after purchasing an additional 547 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
KVUE has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft boosted their price target on Kenvue from $23.00 to $24.00 and gave the company a "buy" rating in a research note on Wednesday, August 7th. UBS Group increased their target price on Kenvue from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Wednesday, August 7th. JPMorgan Chase & Co. boosted their price target on Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a research note on Friday, October 11th. Royal Bank of Canada downgraded shares of Kenvue from an "outperform" rating to a "sector perform" rating and set a $24.00 price objective on the stock. in a research note on Tuesday, September 24th. Finally, Jefferies Financial Group assumed coverage on shares of Kenvue in a report on Tuesday, September 24th. They issued a "buy" rating and a $27.00 target price on the stock. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Hold" and a consensus target price of $22.64.
Check Out Our Latest Report on Kenvue
Kenvue Price Performance
NYSE:KVUE traded up $0.71 on Friday, hitting $23.68. The company had a trading volume of 16,635,437 shares, compared to its average volume of 16,248,485. Kenvue Inc. has a 52 week low of $17.67 and a 52 week high of $23.72. The company has a current ratio of 0.99, a quick ratio of 0.68 and a debt-to-equity ratio of 0.69. The stock has a market capitalization of $45.35 billion, a price-to-earnings ratio of 40.83, a PEG ratio of 2.94 and a beta of 1.36. The firm has a 50 day moving average of $22.65 and a two-hundred day moving average of $20.54.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.28 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.01. The company had revenue of $3.90 billion during the quarter, compared to analysts' expectations of $3.92 billion. Kenvue had a return on equity of 21.80% and a net margin of 7.23%. Kenvue's revenue was down .4% compared to the same quarter last year. During the same period in the prior year, the company earned $0.31 EPS. On average, research analysts anticipate that Kenvue Inc. will post 1.08 earnings per share for the current year.
Kenvue Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be issued a dividend of $0.205 per share. This represents a $0.82 annualized dividend and a dividend yield of 3.46%. The ex-dividend date of this dividend is Wednesday, November 13th. Kenvue's dividend payout ratio (DPR) is currently 141.38%.
About Kenvue
(
Free Report)
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
Further Reading
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
